<DOC>
	<DOCNO>NCT00837954</DOCNO>
	<brief_summary>The purpose trial demonstrate bleeding time suture hole construction arterial bypass anastomosis shorter treatment Lyostypt® Surgicel®</brief_summary>
	<brief_title>Trial Evaluate Hemostatic Effect Lyostypt® Versus Surgicel® Arterial Bypass Anastomosis</brief_title>
	<detailed_description>Hemostasis peripheral vascular surgery make difficult need direct arterial arterial graft suture well systemic anticoagulation prevent thrombosis period vascular occlusion . Polytetrafluorethylene ( PTFE ) one frequently use graft material vascular replacement bypass case autologous vena available ( 1 ) . However , insufficient elasticity PTFE porosity promote development suture hole bleeding ( 2,3 ) cause considerable loss blood prolongation operation ( 2 ) . This study design demonstrate superiority Lyostypt® oxidize cellulose ( Surgicel® ) hemostasis suture hole bleed arterial bypass anastomose vascular reconstruction . Lyostypt® absorbable , wet stable collagen compress make collagen fibril bovine origin . Collagen lead thrombocyte adhesion activation coagulation factor XII . Therefore collagen effective hemostasis . Collagen cell-friendly whereas hemostat significantly disturb cell growth . Advantages collagen fleece fast induction hemostasis , low tissue reaction fast absorption ( 15 ) . Furthermore , collagen show best overall hemostatic agent microvascular surgery . Authors conclude collagen fleece establish fast hemostasis oxidize cellulose resorbed faster oxidize cellulose ( 15 ) .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients indication peripheral vascular reconstruction due peripheral vascular disease ( PVD ) include femorofemoral , femoropopliteal femorocrural reconstruction need crossover include femorofemoral ilacofemoro reconstruction . suture hole bleed peripheral arterial bypass anastomosis use PTFE graft prosthesis Written inform consent Emergency surgery Patients coagulopathy uremia Reoperation within one month location Pregnant Breastfeeding Women Known suspect allergy hypersensitivity use device ( e.g . material bovine origin ) Severe comorbidity ( ASA ≥ 4 ) Life expectancy le 12 month Current immunosuppressive therapy ( 40 mg corticoid per day ezathioprin ) Chemotherapy within last 4 week Radiotherapy treat region within last 2 month Severe psychiatric neurologic diseases Lack compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PTFE Graft</keyword>
	<keyword>Suture Hole Bleeding</keyword>
	<keyword>Hemostasis</keyword>
</DOC>